Contributions
Abstract: PB1865
Type: Publication Only
Background
There are a lot of prognosis criteria for risk stratification of Hodgkin’s lymphoma (HL). The most applicable is the IPS-7, however this score is ignoring a tumor cells phenotype. There are data about dependence survival and antigenic profile of Reed-Sternberg (RS) cells. To determine the clinical significance of bcl-2 and CD30 expression in RS cells of classical HL, we have correlated it’s expression with available IPS criteria and failure-free survival (FFS) after treatment by ABVD (adriamicyn, bleomicyn, vinblastine, dacarbazine)..
Aims
To determine predictive possibility proapoptotic protein bcl-2 and CD30 antigen on RS cells aggregating with criteria IPS
Methods
In study were included 85 previously untreated patients, presented with classical HL between 2002 and January 2016. This retrospective study did not require approval by the Local ethical committee. Inclusion criteria were: a histologically confirmed diagnosis of classical HL, the presence of a fixed in paraffin before treatment a lymph node sample or other diseased tissue, the minimum follow-up was not less than 18 months.
Results
In the study population (n = 85) identified 30 (35%) histological samples bcl-2+, and 55 biopsies (65%), bcl-2. Group bcl-2+ patients had a lower response rate after ABVD chemotherapy - only 24 (28%) patients achieved CR or better result, as compared with 49 patients (57.6%) of the bcl-2 group. Three-year event-free survival (EFS) in bcl-2+ patients had lower 82% vs. 96% than in bcl-2 group (p = 0.018). Multivariate analysis using the Cox proportional hazard model with the inclusion of bcl-2+; CD30 +; bcl-2 + / CD30 +, age 45 and older, B-symptoms, III-IV stage, anemia, decreased serum albumin, increased LDH, leukocytosis revealed that the expression of bcl-2 on RS cells was an independent factor of poor prognosis. 3 year EFS was 52% vs 90% in bcl-2 population (p = 0.022; RR=1,4). The greater relative risk was observed in a population with double expression of bcl-2 and CD30, where the 3-year EFS was 47% (p = 0.012; RR=1,6).
Conclusion
The expression of bcl-2 on HRS cells can be an independent prognostic factor, co-expression of bcl-2 and CD30 can be viewed as a more powerful factor of poor prognosis than bcl-2+ cells.
Session topic: 17. Hodgkin lymphoma - Clinical
Keyword(s): Hodgkin's Lymphoma, CD30, BCL2, Antigen presentation
Abstract: PB1865
Type: Publication Only
Background
There are a lot of prognosis criteria for risk stratification of Hodgkin’s lymphoma (HL). The most applicable is the IPS-7, however this score is ignoring a tumor cells phenotype. There are data about dependence survival and antigenic profile of Reed-Sternberg (RS) cells. To determine the clinical significance of bcl-2 and CD30 expression in RS cells of classical HL, we have correlated it’s expression with available IPS criteria and failure-free survival (FFS) after treatment by ABVD (adriamicyn, bleomicyn, vinblastine, dacarbazine)..
Aims
To determine predictive possibility proapoptotic protein bcl-2 and CD30 antigen on RS cells aggregating with criteria IPS
Methods
In study were included 85 previously untreated patients, presented with classical HL between 2002 and January 2016. This retrospective study did not require approval by the Local ethical committee. Inclusion criteria were: a histologically confirmed diagnosis of classical HL, the presence of a fixed in paraffin before treatment a lymph node sample or other diseased tissue, the minimum follow-up was not less than 18 months.
Results
In the study population (n = 85) identified 30 (35%) histological samples bcl-2+, and 55 biopsies (65%), bcl-2. Group bcl-2+ patients had a lower response rate after ABVD chemotherapy - only 24 (28%) patients achieved CR or better result, as compared with 49 patients (57.6%) of the bcl-2 group. Three-year event-free survival (EFS) in bcl-2+ patients had lower 82% vs. 96% than in bcl-2 group (p = 0.018). Multivariate analysis using the Cox proportional hazard model with the inclusion of bcl-2+; CD30 +; bcl-2 + / CD30 +, age 45 and older, B-symptoms, III-IV stage, anemia, decreased serum albumin, increased LDH, leukocytosis revealed that the expression of bcl-2 on RS cells was an independent factor of poor prognosis. 3 year EFS was 52% vs 90% in bcl-2 population (p = 0.022; RR=1,4). The greater relative risk was observed in a population with double expression of bcl-2 and CD30, where the 3-year EFS was 47% (p = 0.012; RR=1,6).
Conclusion
The expression of bcl-2 on HRS cells can be an independent prognostic factor, co-expression of bcl-2 and CD30 can be viewed as a more powerful factor of poor prognosis than bcl-2+ cells.
Session topic: 17. Hodgkin lymphoma - Clinical
Keyword(s): Hodgkin's Lymphoma, CD30, BCL2, Antigen presentation